Article

Lung

, Volume 186, Issue 6, pp 381-386

Lung Function Response to 12-week Treatment with Combined Inhalation of Long-acting β2 Agonist and Glucocorticoid According to ADRB2 Polymorphism in Patients with Chronic Obstructive Pulmonary Disease

  • Woo Jin KimAffiliated withDepartment of Internal Medicine, College of Medicine, Kangwon National University
  • , Yeon-Mok OhAffiliated withDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine
  • , Joohon SungAffiliated withDepartment of Cancer Prevention and Epidemiology, National Cancer Center
  • , Tae-Hyung KimAffiliated withDivision of Pulmonology, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine
  • , Jin Won HuhAffiliated withDepartment of Internal Medicine, Ilsan Paik Hospital, Inje University
  • , Hoon JungAffiliated withDepartment of Internal Medicine, Ilsan Paik Hospital, Inje University
  • , Ji-Hyun LeeAffiliated withDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Bundang CHA Hospital, College of Medicine, Pochon CHA University
  • , Eun-Kyung KimAffiliated withDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Bundang CHA Hospital, College of Medicine, Pochon CHA University
  • , Jin Hwa LeeAffiliated withDepartment of Internal Medicine, Ewha Womans University Mokdong Hospital, College of Medicine, Ewha Womans University
    • , Sang-Min LeeAffiliated withDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Clinical Research Institute, Seoul National University Hospital, Lung Institute, Medical Research Center, Seoul National University College of Medicine
    • , Sangyeub LeeAffiliated withDivision of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University Anam Hospital
    • , Seong Yong LimAffiliated withDepartment of Internal Medicine, College of Medicine, Kangwon National UniversityDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
    • , Tae Rim ShinAffiliated withDepartment of Internal Medicine, College of Medicine, Kangwon National UniversityDepartment of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine
    • , Ho Il YoonAffiliated withDepartment of Internal Medicine, College of Medicine, Kangwon National UniversityRespiratory Center, Seoul National University Bundang Hospital, Department of Internal Medicine, Seoul National University College of Medicine
    • , Sung-Youn KwonAffiliated withDepartment of Internal Medicine, College of Medicine, Kangwon National UniversityRespiratory Center, Seoul National University Bundang Hospital, Department of Internal Medicine, Seoul National University College of Medicine
    • , Sang Do LeeAffiliated withDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Recent reports suggest that β2-adrenergic receptor (ADRB2) genotypes are associated with therapeutic responses to β2 agonists in asthmatics. However, few studies have investigated therapeutic responses to β2 agonists in chronic obstructive pulmonary disease (COPD) patients. This study investigated immediate bronchodilator response and lung function responses following a 12-week treatment with a long-acting β2 agonist combined with a steroid inhaler in patients with COPD with various ADRB2 genotypes. One hundred four patients with chronic obstruction were genotyped for codon 16 and 27 polymorphisms of the ADRB2 gene. The immediate bronchodilator response to β2-agonist treatment was evaluated after inhalation of 400 μg salbutamol. In addition, long-term response was evaluated using observed change in spirometric values before and after the treatment with salmeterol (50 μg) combined with fluticasone propionate (500 μg) inhalation twice daily for 12 weeks. In terms of codon 16 variants, the immediate bronchodilator response to salbutamol was 6.4 ± 0.8% (% predicted value) in Arg/Arg patients, 4.9 ± 0.7% in Arg/Gly patients, and 5.8 ± 1.2% in Gly/Gly patients (p = 0.418). The FEV1 changes following the 12-week treatment were 7.0 ± 1.2% in Arg/Arg patients, 3.0 ± 1.5% in Arg/Gly patients, and 7.2 ± 1.2% in Gly/Gly patients (p = 0.229). Similarly, there was no difference between codon 27 variants in terms of immediate bronchodilator response or FEV1 changes after 12 weeks of treatment. We were unable to demonstrate an association between ADRB2 genotype and the effect on lung function of 12-week treatment with combined long-acting β2 agonist and glucocorticoid inhalation or on the immediate bronchodilator response to a short-acting β2 agonist in patients with COPD.

Keywords

β-agonist COPD Polymorphism